Wire · operational-macro
FDA Approves Mavacamten for Pediatric Patients With Obstructive HCM
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 October 2026 · Fusion42 review
The FDA has expanded approval of mavacamten to include pediatric patients with obstructive hypertrophic cardiomyopathy (oHCM) weighing 30 kg or more, based on the SCOUT-HCM trial showing significant reduction in LVOT gradients and maintained safety. Mavacamten is now the only FDA-approved therapy for pediatric oHCM, broadening treatment options beyond adult indications.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 30 Sep 2026 and 2 Oct 2026.
◆ ◆ The Wire takeaway
You have a new FDA-approved route to treat pediatric oHCM that could open early market access and differentiate your offering from traditional beta-blocker therapies. This approval cracks open the paediatric segment, where few options existed, signalling a rare chance to build early expertise and trust.
◆ Coverage
3 sources · first reported 30 Sep 2026 · latest 2 Oct 2026
◆ Related on Wire
◆ Topics